2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.25 (Poster) BURDEN OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION ON PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) FROM THE PERSPECTIVE OF PATIENTS AND CAREGIVERS

PP01.25 (Poster) BURDEN OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION ON PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) FROM THE PERSPECTIVE OF PATIENTS AND CAREGIVERS

Back to course

Pdf Summary

The burden of chemotherapy-induced myelosuppression (CIM) on patients with extensive-stage small cell lung cancer (ES-SCLC) and their caregivers was evaluated in a cross-sectional survey. The study included 110 ES-SCLC patients and 24 caregivers. Patients reported experiencing CIM-related symptoms and complications, with 93.6% reporting CIM-attributable symptoms. The most commonly reported symptoms were thrombocytopenia, neutropenia, anemia, and serious infections. Patients spent an average of nearly 9 hours per week receiving care for CIM, rated as "very or extremely bothersome" by 40.9% of patients. Caregivers spent an average of 30 hours per week caring for their family members with CIM, with 30.4% rating it as "very bothersome". 39.6% of patients had changes to their chemotherapy regimens, and 73% of patients and 92% of caregivers felt the changes were "moderate" or "significant". Patients and caregivers reported feeling "very or extremely" stressed, worried, and anxious about these changes. The functional status of patients, as measured by the Functional Assessment of Cancer Therapy-Lung instrument, was below the US average, with 64.5% indicating being unable to complete normal daily activities. Patients and caregivers expressed substantial concern, distress, worry, and anxiety related to the changes in chemotherapy. The study highlights the substantial burden associated with CIM among patients with ES-SCLC and their caregivers and emphasizes the need for healthcare providers to consider the real-world burden and emotional impact of CIM when making treatment decisions.

Asset Subtitle

Ivo Abraham

Keywords

chemotherapy-induced myelosuppression

ES-SCLC

caregivers

symptoms

complications

burden

changes

stress

functional status

treatment decisions